Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient

Table 2 Clinical characteristics of patients with FOLFOX therapy related pulmonary disease treated with discontinuation of chemotherapy

Reference	Patient Gender/Age	Preexisting lung disease with the exception of lung metastasis	Smoking	Symptomes	0xygen supplement	Pulmonary function tests
Gagnadoux	F/60	None	No	Cough, progressive dyspnea on exertion	None	FEV1 1.980 L (90%) TLC 4.207 L (90%) DL_CO 4.4 ml/mmHg/min (59%)
Ruiz Casado	M/67	CT: some signs of pulmonary fibrosis in the basal portions	NA	None	None	NA
Wilcox	F/77	None	No	Dry cough, dyspnea on exertion	None	Normal lung volumes DL_CO 9.3 ml/mmHg/min (54%)
Park	M/76	Bronchial asthma	Ex-smoker 40 pack years	General systemic weakness, loss of appetite	None	FVC 2.26 L (95%) FEV 1 1.46 L (92%) DL_CO 10,8 ml/min/mmHg (109%)
Basyigit	M/60	None	Ex-smoker 14 pack years	Dyspnea on exertion	None	NA

FEV1 Forced Expiratory Volume In One Second, FVC Forced Vital Capacity, TLC Total Lung Capacity, DL _CO Diffusing Capacity of carbon monoxide, NA Not Available

ISSN: 1471-2407